Skip to main content

Pyrazinamide Pregnancy and Breastfeeding Warnings

Medically reviewed by Last updated on Jan 23, 2023.

Pyrazinamide Pregnancy Warnings

Animal studies have not been reported. There are no controlled data in human pregnancy.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

Use is not recommended unless clearly needed.

US FDA pregnancy category: C

See references

Pyrazinamide Breastfeeding Warnings

Caution is recommended; benefit to mother should outweigh risk to the infant.
-Some experts recommend: A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.

Excreted into human milk: Yes

-The WHO classifies this drug as compatible with breastfeeding; the breastfed infant should be monitored for jaundice.
-The US Centers for Disease Control and Prevention and other professional organizations state breastfeeding should not be discouraged in women taking this drug.
-Some experts recommend: Exclusively breastfed infants should be monitored for the signs/symptoms of toxicity (e.g., arthralgia, fever, hepatitis, jaundice, loss of appetite, nausea, rash, thrombocytopenia, vomiting).

See references

References for pregnancy information

  1. "Product Information. Pyrazinamide (pyrazinamide)." VersaPharm Inc (2001):

References for breastfeeding information

  1. "Product Information. Pyrazinamide (pyrazinamide)." VersaPharm Inc (2001):
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. Department of Adolescent and Child Health and Development. UNICEF. World Health Organization "Breastfeeding and maternal medication: recommendations for drugs in the eleventh Who model list of essential drugs." (2014):
  4. Briggs GG, Freeman RK. "Drugs in Pregnancy and Lactation." Philadelphia, PA: Wolters Kluwer Health (2015):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.